Diabetes Drug Actos Linked To Increased Risk Of Bladder Cancer

by fpw | November 22nd, 2011

November 22, 2011

The Food and Drug Administration (FDA) recently issued a warning about the increased risk of bladder cancer in patients taking the diabetes medication, Actos. According to WebMD Health News, the decision was the result of data culminated from a five-year study by the drug’s manufacturer, Takeda Pharmaceuticals, which showed an increase in the risk of the cancer in patients who had taken the drug over long periods of time or in large doses.

The study examined 193,000 diabetes patients taking Actos for an average of two years. Results stated, “Compared to never being exposed to pioglitazone, a duration of pioglitazone therapy longer than 12 months was associated with a 40 percent increase in risk [for bladder cancer].”

Since the decision, Actos has been pulled from European markets in Germany and France, and the FDA has warned doctors to refrain from starting new patients on the drug if they have bladder cancer or have suffered from bladder cancer in the past.

The Actos Drug Injury Lawyers with Ferrer, Poirot & Wansbrough have handled numerous cases for victims of drug injuries. If you suffer from an Actos drug injury, contact us today to discuss your case.

Actos Linked To Bladder Cancer, FDA Issues Warnings

by fpw | August 30th, 2011

August 30, 2011

Now among the list of risks to consider when taking the Type 2 diabetes drug Actos®, is bladder cancer. According to a news release by the Food and Drug Administration (FDA), makers of the drug are now required to label the drug, warning of the increased risk of bladder cancer as well as the still looming concerns for cardiovascular trouble.

The FDA decided to make the change based on findings of a new study that show the risk for bladder cancer increases the longer the patient takes the drug. Actos boomed onto the market after researchers stated the drug might be a good alternative for Avandia users because it presented a lower chance of cardiovascular problems in patients. More recent studies have shown that patients taking Actos may be at a higher risk for heart complications than those taking Avandia.

The FDA has warned physicians to refrain from prescribing Actos to patients currently suffering from bladder cancer and has stated that patients should contact their doctors immediately if any blood or discoloration of urine occurs. Other early warning signs of bladder cancer the FDA pointed out were:

  • Pain and difficulty when urinating
  • Pain in the lower back and abdomen
  • An urgent and repeated need to urinate.

The Actos Injury Attorneys with Ferrer, Poirot & Wansbrough are available to discuss the details of your case anytime. Their experienced team of attorneys may be able to help you settle your case. Contact them by filling out a free online consultation form today!